French firm's drug succeeds in pivotal trial for progressive MS

April 17, 2015 8:00 AM

13 0

LONDON, April 17 (Reuters) - An experimental drug comprising of a high-dose formulation of the food additive biotin has successfully helped patients with progressive multiple sclerosis in a major clinical trial, its French maker said on Friday.

Biotin, also known as vitamin H, is already an approved food additive but the pharmaceutical-grade dose used in biotech company MedDay's drug MD1003 is 300 mg a day, which is 10,000 times the recommended daily food intake.

Read more

To category page